Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Chairman appointment

20th Mar 2008 12:47

Cyprotex PLC20 March 2008 CYPROTEX plc NEWS 20 March 2008 Appointment of New Chairman Cyprotex PLC (LSE:CRX), the drug discovery services and information group,announces that its Non-Executive Director, Mr. Nikolas Sofronis, will assume anew role as Non-Executive Chairman of Cyprotex PLC from 1 April 2008. The role of Executive Chairman was previously held by Mr. Robert MorrissonAtwater, who at the same time also carried out the role Cyprotex's ChiefExecutive Officer. After 1 April 2008, Mr. Robert Morrisson Atwater willcontinue the single role of Chief Executive Officer. Mr. Robert Morrisson Atwater commented: 'As Cyprotex expands, so do pressures onthe role of the Chief Executive Officer. Bearing this in mind, and the Group'swish to comply with best practice and maintain high standards of corporategovernance, I believe Nikolas Sofronis to be an excellent candidate for thisresponsible role. I look forward to working with him.' Mr. Nikolas Sofronis commented: 'I look forward to actively fulfilling the roleof Non-Executive Chairman for Cyprotex. The Group's potential has yet to befully realised. I look forward to taking a more significant role in helping tosteer the Group while also championing the interests of shareholders.' Nikolas Sofronis (43), having graduated from the Athens Bar, is a lawyer bytraining. For the past 17 years, he has worked in numerous high profile assetmanagement organisations. While working for HSBC, Credit Lyonnais, RepublicBank of New York, Paribas SA, amongst other, he has developed a broad base ofcontacts within European pharmaceutical and biotechnology companies. For further information:Cyprotex PLCRobert Morrisson Atwater, CEORussell Gibbs, CFOTel: +44 (0)1625 505 [email protected] Nomura Code Securities LimitedCharles Walker, Corporate FinanceTel: +44 (0)20 7776 [email protected] Media Enquires:WMC CommunicationsSimon MillerTel: +44 (0)20 3178 [email protected] This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

CRX.L
FTSE 100 Latest
Value8,275.66
Change0.00